The NCT05274451 trial, a Phase I study, was designed by Lyell Immunopharma, Inc. Its objective is to evaluate the safety and tolerability of LYL797, a ROR1 CAR-T cell product in patients with relapsed or refractory TNBC and NSCLC. This evidence concerns the gene ROR1 and non-small cell lung carcinoma.